225 related articles for article (PubMed ID: 30098676)
1. Qualitative Research to Explore the Patient Experience of X-Linked Hypophosphatemia and Evaluate the Suitability of the BPI-SF and WOMAC® as Clinical Trial End Points.
Theodore-Oklota C; Bonner N; Spencer H; Arbuckle R; Chen CY; Skrinar A
Value Health; 2018 Aug; 21(8):973-983. PubMed ID: 30098676
[TBL] [Abstract][Full Text] [Related]
2. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study.
Lo SH; Lachmann R; Williams A; Piglowska N; Lloyd AJ
Qual Life Res; 2020 Jul; 29(7):1883-1893. PubMed ID: 32162120
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Brandi ML; Jan de Beur S; Briot K; Carpenter T; Cheong HI; Cohen-Solal M; Crowley RK; Eastell R; Imanishi Y; Imel EA; Ing SW; Insogna K; Ito N; Javaid K; Kamenicky P; Keen R; Kubota T; Lachmann RH; Perwad F; Pitukcheewanont P; Portale A; Ralston SH; Tanaka H; Weber TJ; Yoo HW; Sun W; Williams A; Nixon A; Takeuchi Y
Calcif Tissue Int; 2022 Oct; 111(4):409-418. PubMed ID: 35927518
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
5. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
Briot K; Portale AA; Brandi ML; Carpenter TO; Cheong HI; Cohen-Solal M; Crowley RK; Eastell R; Imanishi Y; Ing S; Insogna K; Ito N; Jan de Beur S; Javaid MK; Kamenicky P; Keen R; Kubota T; Lachmann RH; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Nixon A; Nixon M; Sun W; Williams A; Imel EA
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34548383
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Burden of X-Linked Hypophosphataemia: An Opportunistic Qualitative Study of Patient Statements Generated During a Technology Appraisal.
Ferizović N; Marshall J; Williams AE; Mughal MZ; Shaw N; Mak C; Gardiner O; Hossain P; Upadhyaya S
Adv Ther; 2020 Feb; 37(2):770-784. PubMed ID: 31865548
[TBL] [Abstract][Full Text] [Related]
7. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.
Ruppe MD; Zhang X; Imel EA; Weber TJ; Klausner MA; Ito T; Vergeire M; Humphrey JS; Glorieux FH; Portale AA; Insogna K; Peacock M; Carpenter TO
Bone Rep; 2016 Dec; 5():158-162. PubMed ID: 28326356
[TBL] [Abstract][Full Text] [Related]
8. Qualitative concept elicitation and cognitive debriefing interviews of symptoms, impacts and selected customized PROMIS
Findley A; Middlehurst JM; Howse CA; Clifford MJ; Neill W; Tatlock S; Chen WH; Bracher MG; Patel DS
J Patient Rep Outcomes; 2023 Apr; 7(1):39. PubMed ID: 37079188
[TBL] [Abstract][Full Text] [Related]
9. Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey.
Ito N; Kang HG; Nishida Y; Evins A; Skrinar A; Cheong HI
Endocr J; 2022 Apr; 69(4):373-383. PubMed ID: 34732603
[TBL] [Abstract][Full Text] [Related]
10. The ankle in XLH: Reduced motion, power and quality of life.
Akta C; Wenzel-Schwarz F; Stauffer A; Kranzl A; Raimann A; Kocijan R; Ganger R; Mindler GT
Front Endocrinol (Lausanne); 2023; 14():1111104. PubMed ID: 37033213
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes measures of X-linked hypophosphataemia participants: findings from a prospective cohort study in the UK.
Cole S; Sanchez-Santos MT; Kolovos S; Javaid MK; Pinedo-Villanueva R
Orphanet J Rare Dis; 2023 Feb; 18(1):26. PubMed ID: 36755338
[TBL] [Abstract][Full Text] [Related]
12. X-linked hypophosphatemia: The medical expert's challenges and the patient's concerns on their journey with the disease.
Hamdy NAT; Harvengt P; Usardi A
Arch Pediatr; 2021 Oct; 28(7):612-618. PubMed ID: 34593293
[TBL] [Abstract][Full Text] [Related]
13. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms.
Che H; Roux C; Etcheto A; Rothenbuhler A; Kamenicky P; Linglart A; Briot K
Eur J Endocrinol; 2016 Mar; 174(3):325-33. PubMed ID: 26783348
[TBL] [Abstract][Full Text] [Related]
14. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument.
Johnson CD; Arbuckle R; Bonner N; Connett G; Dominguez-Munoz E; Levy P; Staab D; Williamson N; Lerch MM
Patient; 2017 Oct; 10(5):615-628. PubMed ID: 28332032
[TBL] [Abstract][Full Text] [Related]
15. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study.
Gater A; Abetz-Webb L; Battersby C; Parasuraman B; McIntosh S; Nathan F; Piault EC
Health Qual Life Outcomes; 2011 Oct; 9():88. PubMed ID: 21992720
[TBL] [Abstract][Full Text] [Related]
16. Patient-Centered Research to Support the Development of the Symptoms of Major Depressive Disorder Scale (SMDDS): Initial Qualitative Research.
McCarrier KP; Deal LS; Abraham L; Blum SI; Bush EN; Martin ML; Thase ME; Coons SJ;
Patient; 2016 Apr; 9(2):117-34. PubMed ID: 26113249
[TBL] [Abstract][Full Text] [Related]
17. Reliability and validity of 6 measures of pain, function, and disability for ankle arthroplasty and arthrodesis.
Pinsker E; Inrig T; Daniels TR; Warmington K; Beaton DE
Foot Ankle Int; 2015 Jun; 36(6):617-25. PubMed ID: 25652665
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-mediated mutation of PHEX in rabbit recapitulates human X-linked hypophosphatemia (XLH).
Sui T; Yuan L; Liu H; Chen M; Deng J; Wang Y; Li Z; Lai L
Hum Mol Genet; 2016 Jul; 25(13):2661-2671. PubMed ID: 27126636
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life of X-linked hypophosphatemia in Spain.
Yanes MIL; Diaz-Curiel M; Peris P; Vicente C; Marin S; Ramon-Krauel M; Hernandez J; Broseta JJ; Espinosa L; Mendizabal S; Perez-Sukia L; Martínez V; Palazón C; Piñero JA; Calleja MA; Espin J; Arborio-Pinel R; Ariceta G
Orphanet J Rare Dis; 2022 Jul; 17(1):298. PubMed ID: 35906684
[TBL] [Abstract][Full Text] [Related]
20. Content validity and ePRO usability of the BPI-sf and "worst pain" item with pleural and peritoneal mesothelioma.
Gelhorn HL; Eremenco S; Skalicky AM; Balantac Z; Cimms T; Halling K; Sexton C
J Patient Rep Outcomes; 2017; 2(1):16. PubMed ID: 29749970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
